Q4 2023 InflaRx NV Earnings Call Transcript
Good morning, everyone. Thank you for standing by and thank you for joining InflaRx's conference call to discuss the company's expected development plans for INF904, our orally available C5aR inhibitor with best-in-class potential. Presenting on today's call, we have Niels Riedemann, CEO and Founder; and Camilla Chong, Chief Medical Officer; with Renfeng Guo as CSO and founder; and Thomas Taapken, CFO available during the Q&A session.
During today's presentation, all participants will be in a listen only mode. Please note that today's call is being recorded. The presentation will be followed by a Q&A session where you may ask written or audio questions and please note that you can ask questions only online. I would now like to turn the call over to Dr. Niels Riedemann, CEO and Founder of InflaRx. Niels, please go ahead.
Yes. Thank you so much, Jan. We're really excited to have everyone on the call today to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |